One of the final players in the chain of events that leads to clot formation could prove a good target for a new generation of clot-busting drugs, a new study suggests.
Browse by Speciality Area
All Access Subscription
Get unlimited access to our full publication and article library.
Get Access NowInterested in Group Sales? Learn more